Summary Placental and placental-like alkaline phosphatase (PLAP) levels in the culture media of 87 cell lines of neoplastic and 'normal' origin were measured by a conventional immunosorbent enzymatic assay (IAEA) and by a new immunoradiometric assay (IRMA). The IRMA detected immunoreactive PLAP in 37 of 80 (46%) human epithelial and germ cell cultures, while the IAEA detected PLAP in only 25 (33%). Of the 52 non-germ cell tumour cultures, the IRMA detected expression in 24 (46%) and the IAEA in only 16 (31%). In 17 cases (21 %) the IRMA recorded levels double that of the IAEA, while in five cultures (6%) the reverse was true. The IRMA was much more robust than the IAEA and had considerably lower inter-and intra-assay coefficients of variation (3.75-8.5% vs 5.2-46%). Detection of PLAP(-like) expression by IAEA is dependent on neoplastic expression of enzymically functional molecules and quantification assumes constant enzyme kinetics. PLAP-like material has a higher catalytic rate constant than PLAP and thus will give higher values on a stoichiometric basis in an IAEA. The higher detection rate and levels of PLAP-like material in neoplastic cultures when measured by the IRMA clearly demonstrate ectopic expression of non-enzymatic PLAP and PLAP-like genes. The incidence of PLAP(-like) expression by non-germ cell and possible germ cell tumours has been underestimated and its utility as a tumour marker should be re-examined using assays which measure antigen mass rather than phosphatase activity.
The tissue-specific alkaline phosphatase family consists of at least three variants, each encoded by separate genes (Martin et al., 1990) . These variants are placental alkaline phosphatase (PLAP), germ cell alkaline phosphatase (PLAP-like) and intestinal alkaline phosphatase (IAP). All have been mapped to a gene cluster at human chromosome 2q34-q37 (Griffin et al., 1987; Martin et al., 1990; Millan & Manes, 1988) . Tissue non-specific alkaline phosphatase, also referred to as liver/ kidney/bone type, is not a member of this cluster and is coded on the short arm of chromosome 1 (Stigbrand & Fishman, 1984) .
Placenta-specific alkaline phosphatase (PLAP) is a membrane-bound protein of the placental syncytiotrophoblast. It is a dimer consisting of two identical subunits and has no transmembrane domains. Anchorage to the external side of the plasma membrane is via a glycan-phosphatidylinositol moiety. The function of PLAP is to bind maternal immunoglobulin G (IgG) and transport this protein across the placental barrier. The non-physiological phosphatase activity (pH optimum 10.5, temperature optimum 65°C) is considered to be a secondary reaction of this process (Makiya & Stigbrand, 1992) .
Ectopic expression of this placental antigen by cancers has been recognised for many years. In particular, seminomatous and non-seminomatous testicular germ cell tumours express the germ cell (PLAP-like) isoform. The placental variant is also expressed by some lung and cervix tumours.
Most assays for PLAP and PLAP-like antigens rely on the intrinsic alkaline phosphatase activity of the molecule. Specific antibodies have been raised against PLAP, which also recognise the 98% homologous PLAP-like variant. These are commonly used for immunosorption of PLAP(-like) molecules onto reaction wells prior to measurement of phosphatase activity. However 
Materials and methods
Assay for PLAP PLAP was measured using an enzymatic immunosorbent assay (IAEA) and an in-house immunoradiometric assay (IRMA).
The IAEA was an adaptation of the assay method of McLaughlin et al. (1983) . Monoclonal antibody H 1 7E2 (Travers & Bodmer, 1984) (donated by A. Badley, Unilever Research, Colworth Laboratory, Sharnbrook, Bedfordshire, UK) was absorbed onto the wells of microtitre plates. These were preincubated with serum samples or standards, and levels of captured PLAP and PLAP-like material were determined by colorimetric measurement of the endogenous phosphatase activity (Figure lb) . The activity in samples was compared with standards derived from serial dilution of highly purified PLAP (750IUmg-' Calzyme Laboratories, San Luis Obispo, CA, USA). The detection limit was 0.18 IU l' and the inter-and intra-assay variation were 10-46% and 5.2-13% respectively.
The in-house IRMA for PLAP utilised a monoclonal antibody H7 (InRo BioMedTek, Umea, Sweden) coupled to 1,l-carbonyldiimidazole-activated cellulose (SCIPAC, Sittingbourne, Kent, UK) as solid phase. Monoclonal antibody H17E2 radiolabelled with iodine-125 by the chloramine T method was used for detection (see Figure lc) . Binding was compared with standards of purified PLAP as for the IAEA. Monoclonal antibody H7 recognises epitopes on PLAP close to the glycan-phosphatidylinositol membrane linkage, while H17E2 recognises epitopes on the exposed surface which are separate from the active site of the enzyme (Hoylaert & Milan, 1991 ) (see Figure la) . The (kidney) . Culture media from eight normal urothelia and seven skin keratinocyte preparations were also assayed, together with media from three human and four murine control lines. Most of these cell lines are described in an earlier study (Iles et al., 1990) . Additional media from cultured bladder carcinoma were provided by M. Knowles (Marie Curie Institute, Oxted, Surrey, UK). Additional cervical cancer cell line clones were originated by X. Han and E. Heyderman (St Thomas's Hospital, London, UK) (see Table I ). In all cases the cells were grown to confluence in culture flasks (75 cm2 adherence area). At this stage the medium (10 ml) was exchanged and the culture continued for a further 96 h. The medium was then harvested and stored at -20°C until assayed.
Results
The cell lines and the levels of PLAP/PLAP-like immunoreactivity and enzymic activity present in the culture media are shown in Table I . All seven control cultures had undetectable levels of PLAP-like immunoreactivity or enzyme activity. The IRMA detected immunoreactive PLAP(-like) material in media from 37 of the 80 human cell lines (46%). The IAEA detected PLAP(-like) activity in 25 of these media (33%). In 17 cultures (21%) PLAP levels measured by IRMA were higher than (more than double) those measured by IAEA, while in five cultures (6%) the reverse was true. In 13 cultures (16%) PLAP was detectable by IRMA but not by the IAEA. The converse was true in only one culture (1%).
The incidence of positive findings for cultures of specific tissues/neoplasms was: 8/17 bladder carcinoma, 0/4 breast carcinoma, 5/11 cervical carcinoma, 3/3 choriocarcinoma, 2/2 colorectal, 5/8 testicular germ cell, 1/5 epithelial ovarian, 7/8 oral and respiratory epithelial carcinoma (EC) and squamous cell carcinoma (SCC), 0/2 small-cell lung carcinoma, 0/1 Wilms tumour and 1/1 vulval carcinoma cell lines. Additionally, 3/8 normal skin keratinocyte, 2/7 normal urothelial and 0/3 oral mucosal cell lines were found to have detectable levels of PLAP(-like) antigen in their culture media. None of three human fibroblast control or four murine carcinoma/fibroblast control cell lines had detectable levels of PLAP(-like) antigen in their culture media.
Discussion
Ectopic expression of PLAP, and in particular the homologous germ cell alkaline phosphatase (PLAP-like), has been used as a marker of testicular and ovarian germ cancers (Nathason & Fishman, 1971) . Expression by testicular seminomas and ovarian dysgerminomas might provide a clinical marker of these tumours; they rarely produce human chorionic gonadotrophin (hCG) and never produce alpha-fetoprotein (AFP) (Horwich et al., 1985; Tucker et al., 1985; Lange et al., 1982) . However, some have reported that measurement of PLAP(-like) levels is of little or no clinical value (Nielson et al., 1990; Munro et al., 1991) . Elevated PLAP or PLAP-like activity has also been found in the serum of patients with lung, colorectal and urogenital carcinomas (Fishman et al., 1968; Stigbrand et al., 1982) . PLAP(-like) expression had been demonstrated in extracts from cervical, colorectal, bladder and choriocarcinoma cell lines (Nozawa & Fishman, 1982 (Makiya, 1992 In the present study five culture media had higher levels of PLAP when measured by the enzymic assay. These cell lines were of germ cell origin or known to express the germ cell/PLAP-like alkaline phosphatase gene (KB, Hep2) (Nozawa & Fishman, 1982; Luduena & Sussman, 1976) . There is a high degree of homology between placental and germ cell alkaline phosphatase, and both are recognised by H7 and H17E2 antibodies (Milan & Stigbrand, 1983; Travers & Bodmer, 1984) . Thus antigenic variation is not likely to account for the differences in assay estimation of PLAP/ PLAP-like levels. The seven amino acid substitutions found in the PLAP-like isoform result in a higher catalytic rate constant (Watanbe et al., 1991; Hoylaerts et al., 1992) . Thus, on a stoichiometric basis PLAP-like material will give higher values than the authentic placental isoform when measured by an enzymatic assay.
Immunoreactive PLAP(-like) material was found to be expressed by a number of cell types, in particular testicular germ cell tumours, choriocarcinomas, squamous cell and epidermoid carcinomas of the oral and respiratory tract, cervical and bladder cancers. Since high levels of enzymatic PLAP were also found in the culture media from testicular germ cell cancers it is likely that this material is the germ cell, PLAP-like, isoform. It is interesting to note that all but two of these lines (WG007 and PJ007) had originated from nonseminomatous testicular tumours which no longer secrete hCG or AFP in vitro (Iles et al., 1987) .
For most of the remaining cultures, including the choriocarcinomas, immunoreactive levels exceeded enzymatic levels. Whether this is due to degradation of enzyme activity upon storage or production of defective PLAP has yet to be determined. Our preliminary studies have shown that immunoreactive PLAP in the serum from various cancer patients can consist of the dimeric and the monomeric forms. However, there is considerable heterogeneity in the molecular size of both forms. This could be due to variable glycosylation, a truncated peptide sequence and, as has been shown for PLAP produced by the KB cell line, expression of both PLAP and PLAP-like (germ cell) genes resulting in a hybrid dimer (Luduena & Sussman, 1976 ; R. Iles and T.E.J. Ind, unpublished observations). Nevertheless, this study clearly shows that the incidence of PLAP and PLAP-like gene expression by non-germ cell tumours has been underestimated. Further application of purely immunometric PLAP assays is warranted in order to re-evaluate PLAP as a tumour marker not only of seminomas but of non-germ cell carcinomas. We have already demonstrated elevated serum levels of immunoreactive PLAP in patients with malignant pelvic disease (Ind et al., 1993a) . Furthermore, aberrant levels of PLAP have been shown to be associated with Down's syndrome pregnancies when measured by this IRMA but not by the IAEA (Brock et al., 1990; Ind et al., 1993b) . Similarly, we have demonstrated an association between PLAP levels and blood groups which had not previously been recognised (Ind et al., 1993c) .
In conclusion, immunoreactive determination of PLAP and PLAP-like levels may reflect the actual expression more closely than determination based on phosphatase activity.
This may enhance the role of PLAP as an effective tumour marker.
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